Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))

Rodney P. Rocconi; Bradley J. Monk; Adam Walter; Thomas J. Herzog; Evanthia Galanis; Luisa Manning; Ernest Bognar; Gladice Wallraven; Laura Stanbery; Phylicia Aaron; Neil Senzer; Robert L. Coleman; John Nemunaitis

doi:10.1016/j.ygyno.2022.11.010

Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))

Rodney P. Rocconi, Bradley J. Monk, Adam Walter, Thomas J. Herzog, Evanthia Galanis, Luisa Manning, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Phylicia Aaron, Neil Senzer, Robert L. Coleman, John Nemunaitis

Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors regret that there was an error on the demographics table (Table 1) in the published version. The number of neoadjuvant and adjuvant patients was incorrect. This error did not affect the results or interpretation of the manuscript, and did not alter the statistical significance of the primary endpoints (PFS and OS) of the study. The authors would like to apologise for any inconvenience caused.

Original language	English (US)
Pages (from-to)	173
Number of pages	1
Journal	Gynecologic oncology
Volume	169
DOIs	https://doi.org/10.1016/j.ygyno.2022.11.010
State	Published - Feb 2023

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/j.ygyno.2022.11.010

Fingerprint

Dive into the research topics of 'Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))'. Together they form a unique fingerprint.

Cite this

Rocconi, R. P., Monk, B. J., Walter, A., Herzog, T. J., Galanis, E., Manning, L., Bognar, E., Wallraven, G., Stanbery, L., Aaron, P., Senzer, N., Coleman, R. L., & Nemunaitis, J. (2023). Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009)). Gynecologic oncology, 169, 173. https://doi.org/10.1016/j.ygyno.2022.11.010

Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009)). / Rocconi, Rodney P.; Monk, Bradley J.; Walter, Adam et al.

In: Gynecologic oncology, Vol. 169, 02.2023, p. 173.

Research output: Contribution to journal › Comment/debate › peer-review

Rocconi, RP, Monk, BJ, Walter, A, Herzog, TJ, Galanis, E, Manning, L, Bognar, E, Wallraven, G, Stanbery, L, Aaron, P, Senzer, N, Coleman, RL & Nemunaitis, J 2023, 'Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))', Gynecologic oncology, vol. 169, pp. 173. https://doi.org/10.1016/j.ygyno.2022.11.010

Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L et al. Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009)). Gynecologic oncology. 2023 Feb;169:173. doi: 10.1016/j.ygyno.2022.11.010

Rocconi, Rodney P. ; Monk, Bradley J. ; Walter, Adam et al. / Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009)). In: Gynecologic oncology. 2023 ; Vol. 169. pp. 173.

@article{1b68d03eb67a41d89949ed6784d98428,

title = "Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))",

abstract = "The authors regret that there was an error on the demographics table (Table 1) in the published version. The number of neoadjuvant and adjuvant patients was incorrect. This error did not affect the results or interpretation of the manuscript, and did not alter the statistical significance of the primary endpoints (PFS and OS) of the study. The authors would like to apologise for any inconvenience caused.",

author = "Rocconi, {Rodney P.} and Monk, {Bradley J.} and Adam Walter and Herzog, {Thomas J.} and Evanthia Galanis and Luisa Manning and Ernest Bognar and Gladice Wallraven and Laura Stanbery and Phylicia Aaron and Neil Senzer and Coleman, {Robert L.} and John Nemunaitis",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2023",

month = feb,

doi = "10.1016/j.ygyno.2022.11.010",

language = "English (US)",

volume = "169",

pages = "173",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680] (Gynecologic Oncology (2021) 161(3) (676–680), (S0090825821002298), (10.1016/j.ygyno.2021.03.009))

AU - Rocconi, Rodney P.

AU - Monk, Bradley J.

AU - Walter, Adam

AU - Herzog, Thomas J.

AU - Galanis, Evanthia

AU - Manning, Luisa

AU - Bognar, Ernest

AU - Wallraven, Gladice

AU - Stanbery, Laura

AU - Aaron, Phylicia

AU - Senzer, Neil

AU - Coleman, Robert L.

AU - Nemunaitis, John

PY - 2023/2

Y1 - 2023/2

N2 - The authors regret that there was an error on the demographics table (Table 1) in the published version. The number of neoadjuvant and adjuvant patients was incorrect. This error did not affect the results or interpretation of the manuscript, and did not alter the statistical significance of the primary endpoints (PFS and OS) of the study. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that there was an error on the demographics table (Table 1) in the published version. The number of neoadjuvant and adjuvant patients was incorrect. This error did not affect the results or interpretation of the manuscript, and did not alter the statistical significance of the primary endpoints (PFS and OS) of the study. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85146921941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146921941&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2022.11.010

DO - 10.1016/j.ygyno.2022.11.010

M3 - Comment/debate

C2 - 36456375

AN - SCOPUS:85146921941

SN - 0090-8258

VL - 169

SP - 173

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this